Next Article in Journal
Embryological Results of Couples Undergoing ICSI-ET Treatments with Males Carrying the Single Nucleotide Polymorphism rs175080 of the MLH3 Gene
Next Article in Special Issue
Histone H3 Acetyl K9 and Histone H3 Tri Methyl K4 as Prognostic Markers for Patients with Cervical Cancer
Previous Article in Journal
An Overview of Multimodal Neuroimaging Using Nanoprobes
Previous Article in Special Issue
mir-660-p53-mir-486 Network: A New Key Regulatory Pathway in Lung Tumorigenesis
Review

Epigenetic Alterations in Parathyroid Cancers

1
Laboratory of Experimental Endocrinology, IRCCS Istituto Ortopedico Galeazzi, 20161 Milan, Italy
2
Endocrinology Unit, Department of Biomedical Sciences for Health, University of Milan, IRCCS Istituto Ortopedico Galeazzi, 20097 Milan, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Nicoletta Sacchi
Int. J. Mol. Sci. 2017, 18(2), 310; https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18020310
Received: 20 November 2016 / Accepted: 27 January 2017 / Published: 1 February 2017
(This article belongs to the Special Issue Cancer Epigenetics)
Parathyroid cancers (PCas) are rare malignancies representing approximately 0.005% of all cancers. PCas are a rare cause of primary hyperparathyroidism, which is the third most common endocrine disease, mainly related to parathyroid benign tumors. About 90% of PCas are hormonally active hypersecreting parathormone (PTH); consequently patients present with complications of severe hypercalcemia. Pre-operative diagnosis is often difficult due to clinical features shared with benign parathyroid lesions. Surgery provides the current best chance of cure, though persistent or recurrent disease occurs in about 50% of patients with PCas. Somatic inactivating mutations of CDC73/HRPT2 gene, encoding parafibromin, are the most frequent genetic anomalies occurring in PCas. Recently, the aberrant DNA methylation signature and microRNA expression profile have been identified in PCas, providing evidence that parathyroid malignancies are distinct entities from parathyroid benign lesions, showing an epigenetic signature resembling some embryonic aspects. The present paper reviews data about epigenetic alterations in PCas, up to now limited to DNA methylation, chromatin regulators and microRNA profile. View Full-Text
Keywords: parathyroid cancers; parathormone (PTH); DNA methylation; histones; methyltransferases; microRNAs parathyroid cancers; parathormone (PTH); DNA methylation; histones; methyltransferases; microRNAs
Show Figures

Graphical abstract

MDPI and ACS Style

Verdelli, C.; Corbetta, S. Epigenetic Alterations in Parathyroid Cancers. Int. J. Mol. Sci. 2017, 18, 310. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18020310

AMA Style

Verdelli C, Corbetta S. Epigenetic Alterations in Parathyroid Cancers. International Journal of Molecular Sciences. 2017; 18(2):310. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18020310

Chicago/Turabian Style

Verdelli, Chiara, and Sabrina Corbetta. 2017. "Epigenetic Alterations in Parathyroid Cancers" International Journal of Molecular Sciences 18, no. 2: 310. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms18020310

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop